Histide

Executive Summary

Histide is a Paris-based private biotechnology company pioneering a novel platform of non-mutagenic extracellular therapeutics called Cell Recoding Molecules (CRM). Unlike gene editing or cell therapy, Histide's CRM platform leverages the cell's intrinsic signaling pathways to redirect cell fate without altering DNA. This approach aims to address a wide range of diseases by modulating cellular behavior through microenvironmental cues. Founded in 2008, Histide has developed deep expertise in signal transduction and cellular sensing, positioning it to potentially unlock new therapeutic modalities. The company operates as an intellectual property platform, suggesting a licensing or partnership-driven business model. While specific financials and pipeline details are not publicly disclosed, the platform's broad applicability could attract significant interest from larger biopharma seeking innovative extracellular agents. Histide's progress remains early-stage, but the technology represents a differentiated approach in the biologics space.

Upcoming Catalysts (preview)

• Q4 2026Preclinical proof-of-concept data for lead CRM program40% success
• H2 2026Strategic partnership or licensing agreement for CRM platform35% success
• 2027IND or equivalent regulatory filing for first candidate20% success